Investors

Printer Friendly Version View printer-friendly version
Download PDF Download PDF
BrainStorm Initiated Technology Transfer to City of Hope for U.S. Production of NurOwn® for Phase 3 ALS Study

HACKENSACK, N.J., PETACH TIKVA, Israel and DUARTE, Calif., May 16, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has begun training the cell manufacturing team at City of Hope's Center for Biomedicine and Genetics to produce clinical supplies of NurOwn® adult stem cells for the company's randomized, double-blind, multi-dose Phase 3 clinical study in patients with Amyotrophic Lateral Sclerosis (ALS).  City of Hope will be the clinical supplier for all U.S. medical centers participating in the Phase 3 trial.

BrainStorm Cell Therapeutics

"City of Hope is one of the world's pre-eminent cell product manufacturing centers," said Chaim Lebovits, President and CEO of BrainStorm. "The transfer of our proprietary autologous cell production technology to City of Hope's production team reflects the rapid progress we are making in preparing for our Phase 3 ALS clinical study and will ensure that we have adequate high-quality cell-production capacity in place when we begin the Phase 3 study.  We welcome them as a clinical partner and appreciate their commitment to the success of this important clinical program."

"BrainStorm's NurOwn technology represents an innovative approach to treating ALS. City of Hope is excited to play a role in treating this devastating disease," said Joseph Gold, PhD, Director of manufacturing at the Center for Biomedicine and Genetics.       

About City of Hope  
City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as one of only 47 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world.  City of Hope is located in Duarte, California, just northeast of Los Angeles, with community clinics throughout Southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation, diabetes and numerous breakthrough cancer drugs based on technology developed at the institution. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn® has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.  For more information, visit the company's website at www.brainstorm-cell.com.

Safe-Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements.  The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.  These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.  The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Contacts

Brainstorm Cell Therapeutics

Media:

Uri Yablonka
BrainStorm Cell Therapeutics Inc.
Phone: 646-666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com

City Of Hope:

Letisia Marquez
Senior Media Relations Specialist
City of Hope
Phone: 626-218-3398
lemarquez@coh.org

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-initiated-technology-transfer-to-city-of-hope-for-us-production-of-nurown-for-phase-3-als-study-300458174.html

SOURCE BrainStorm Cell Therapeutics Inc.